Newstral
Article
Forbes on 2022-07-25 15:23
Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
Related news
Biotech startup Zymergen nabs $130 million from SoftbankTechCrunch
As Biology Manufacturing Company Zymergen Implodes, Correspondence With SEC Showed Early DoubtsForbes
Ginkgo Residential buys apartment complex mecktimes.com
Ginkgoyaledailynews.com
- BZymergen Rises 21% in Market Debutbarrons.com
Markets Live: Profits prove paltrySydney Morning Herald
Embattled Vancouver biotech gets another FDA rebukebizjournals.com
SA biotech buys Birmingham companybizjournals.com
BFIT, Ginkgo to team on new biotech manufacturing degreebizjournals.com
Griezmann: Barcelona fined paltry 300 euros for tapping up strikervanguardngr.com
From Akero to Zymergen, 20 Bay Area biotech companies to watch around JPM19bizjournals.com
The rise and fall of Zymergen: Can biotech veteran Jay Flatley save the company?bizjournals.com
Homework: Ginkgo Fest at Highland Parktriblive.com
Ginkgo Residential buys another Triad complex — this one for $30.2Mbizjournals.com
Biotech billionaire buys Los Angeles Timespunchng.com
Seattle biotech Adaptive buys San Francisco firmseattletimes.com
Switzerland’s Novartis buys US biotech firm SpinifexThe Findlay Courier
Switzerland's Novartis buys US biotech firm Spinifexabc3340.com
Top two executives at embattled Cambridge biotech Aegerion resignbizjournals.com
The Great Ginkgo Leaf Dump Is HereThe Atlantic